Cover image of the article: Evaluation of potency of measles vaccine used in Iran: comparison of WHO and NIBSC method in cell culture

Image Credit:Iran J Pharm Res

Evaluation of potency of measles vaccine used in Iran: comparison of WHO and NIBSC method in cell culture

Authors

Shohreh Tavajohi1, 2, Hossein Rastegar1, Seyed Nasser Ostad3, Seyed Mehdi Rezayat2, Mohammad Hossein Ghahremani3,*

Abstract

Measles has been a major cause of illness and death in children and vaccination against the disease is part of the WHO global immunization program. A suitable vaccine should create maximum immune response against the pathogen and must be safe for the user. Thus, after production, vaccines must be analyzed and controlled by the producer and confirm by relevant governmental organizations. The Food and Drug Control Lab (FDCL), Ministry of Health, is the secondary control center on potency of vaccines in Iran. In this study, we have set up the WHO and NIBSC methods in FDCL and compare these methods on determining the potency of measles vaccine.

 

 

Measles vaccines were obtained from Razi Institute Iran. Nine dilutions of vaccine (10-1 to 10-5) in 0.5 log interval were mixed with Vero cell suspension and seeded. In WHO method, the cells were incubated at 36°C for 10 days, during which the cells were checked for cytopatic changes everyday. To set up the assay, we tested the vaccine dilution with four different cell suspensions (2×105-5×104/well) and four different concentration of serum (2.5-10%). Based on our results, in the assays, 5% serum and 1×105 cells were used. The potency assay was performed with six different vaccines produced in one batch and the mean potency for Measles was 104.32 ± 0.24 CCID50/vial for a ten-dose vial. In NIBSC method following seeding of Vero cells, the medium was removed after 3 hours and overlay was added. Then the plates were incubated at 35°C for 10 days. After incubation period, the overlay was removed, the plaques were stained with methyl violet and counted. This assay was repeated three times and the mean of the results was 5.83 ± 0.03 log10 PFU/dose.

 

 

In this study, we have set up the WHO and NIBSC methods and results indicated that the potency of the vaccine is in acceptable range in either method. Furthermore, the WHO method is simple and less time consuming compared to NIBSC which is complicated and requires more effort to produce reproducible results.

 

 

Highlights

How to Cite:Tavajohi S, Rastegar H, Ostad SN, Rezayat SM, Ghahremani MH. Evaluation of potency of measles vaccine used in Iran: comparison of WHO and NIBSC method in cell culture. Iran J Pharm Res. 2022;4(3):e128239. doi: https://doi.org/10.22037/ijpr.2010.631

Copyright

© 2022, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

5
May
2018
Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)

Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)

Abbas Shafyi,
Ashraf Mohammadi

Shafyi A, Mohammadi A. Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017). Jundishapur J Microbiol. 2018;11(5):e60725. doi: https://doi.org/10.5812/jjm.60725

1
Dec
2013
Post-Vaccination Immunity Against Measles in Under Twenty-Five-Year-Old Population of Ahvaz, Southwest of Iran

Post-Vaccination Immunity Against Measles in Under Twenty-Five-Year-Old Population of Ahvaz, Southwest of Iran

Abdolhussein Shakurnia,
Seyed Mohammad Alavi,
Reza Norouzirad,
Amir Arsalan Sarajian,
Ghodratollah Shakerinejad

Shakurnia A, Alavi SM, Norouzirad R, Sarajian AA, Shakerinejad G. Post-Vaccination Immunity Against Measles in Under Twenty-Five-Year-Old Population of Ahvaz, Southwest of Iran. Jundishapur J Microbiol. 2013;6(10):e7707. doi: https://doi.org/10.5812/jjm.7707

9
Jul
2019
Assessment of Routine Measles Vaccine Effectiveness Among Children Referring to Tertiary Fever Hospital in Egypt

Assessment of Routine Measles Vaccine Effectiveness Among Children Referring to Tertiary Fever Hospital in Egypt

John Rene Labib,
Eman Hany Elsebaie,
Shaimaa A.M. Abd El Fatah,
Silvia Farouk Shalaby,
Engy El Khateeb

Labib JR, Elsebaie EH, Abd El Fatah SA, Shalaby SF, El Khateeb E. Assessment of Routine Measles Vaccine Effectiveness Among Children Referring to Tertiary Fever Hospital in Egypt. Arch Pediatr Infect Dis. 2019;7(3):e90407. doi: https://doi.org/10.5812/pedinfect.90407

31
Jul
2007

Evaluation of Primary Failure of New Measles Vaccine and Secondary Failure of Previous Measles Vaccine After Mass Vaccination in Military Cadets in Iran

Gholamali Ghorbani,
Kazem Ahmadi,
Hamidreza Ghadimi

Ghorbani G, Ahmadi K, Ghadimi H. Evaluation of Primary Failure of New Measles Vaccine and Secondary Failure of Previous Measles Vaccine After Mass Vaccination in Military Cadets in Iran. Arch Clin Infect Dis. 2007;2(3):. doi:

8
Sep
2012
Seroprevalence of measles, mumps and rubella Antibodies in 18 months and 6.5 years old children: 6 months after measles-mumps-rubella (MMR) vaccination

Seroprevalence of measles, mumps and rubella Antibodies in 18 months and 6.5 years old children: 6 months after measles-mumps-rubella (MMR) vaccination

Ahmad Shamsizadeh,
Roya Nikfar,
Manoochehr Makvandi,
Makvandi Hakimzadeh,
Mohsen Alisamir,
Tahereh Ziaei

Shamsizadeh A, Nikfar R, Makvandi M, Hakimzadeh M, Alisamir M, et al. Seroprevalence of measles, mumps and rubella Antibodies in 18 months and 6.5 years old children: 6 months after measles-mumps-rubella (MMR) vaccination. Jundishapur J Microbiol. 2012;5(4):578-581. doi: https://doi.org/10.5812/jjm.4563

More by these authors

Shohreh TavajohiPubMedScholar
Hossein RastegarPubMedScholar
Seyed Nasser OstadPubMedScholar
Seyed Mehdi RezayatPubMedScholar
Mohammad Hossein GhahremaniPubMedScholar
Share
Cited by
Metrics
Indexed in